Eilean Therapeutics Unveils Groundbreaking JAK2 Inhibitor ZE74-0282 at ASH 2025 Eilean Therapeutics is set to present its innovative JAK2-JH2/V617F inhibitor ZE74-0282 at ASH 2025 and begin clinical studies soon.

Eilean Therapeutics Unveils Groundbreaking JAK2 Inhibitor ZE74-0282 at ASH 2025 #USA #Dover #Eilean_Therapeutics #JAK2_Inhibitor #ASH_2025